NO20016406L - Höyselektive reopptaksinhibitorer for norepinefrin - Google Patents

Höyselektive reopptaksinhibitorer for norepinefrin

Info

Publication number: NO20016406L
Authority: NO; Norway
Prior art keywords: norepinephrine; reuptake inhibitors; high selective; selective reuptake; inhibitors
Prior art date: 1999-07-01

Application number

NO20016406A

Other languages

English (en)

Norwegian (no)

Other versions

NO20016406D0 (no

Inventor

Erik Ho Fong Wong

Saeeduddin Ahmed

Robert Clyde Marshall

Robert Mcarthur

Duncan Paul Taylor

Lars Birgerson

Pasquale Cetera

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-01

Filing date

2001-12-28

Publication date

2002-02-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20016406(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-28 Application filed by Upjohn Co filed Critical Upjohn Co

2001-12-28 Publication of NO20016406D0 publication Critical patent/NO20016406D0/no

2002-02-19 Publication of NO20016406L publication Critical patent/NO20016406L/no

Links

SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229960002748 norepinephrine Drugs 0.000 title 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Pregnancy & Childbirth (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20016406A 1999-07-01 2001-12-28 Höyselektive reopptaksinhibitorer for norepinefrin NO20016406L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US14196899P	1999-07-01	1999-07-01
US14413199P	1999-07-16	1999-07-16
US15825699P	1999-10-06	1999-10-06
US17038199P	1999-12-13	1999-12-13
PCT/US2000/017256 WO2001001973A2 (en)	1999-07-01	2000-06-22	Highly selective norepinephrine reuptake inhibitors and methods of using the same

Publications (2)

Publication Number	Publication Date
NO20016406D0 NO20016406D0 (no)	2001-12-28
NO20016406L true NO20016406L (no)	2002-02-19

Family

ID=27495506

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO20016406A NO20016406L (no)	1999-07-01	2001-12-28	Höyselektive reopptaksinhibitorer for norepinefrin
NO20091159A NO20091159L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091158A NO20091158L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091168A NO20091168L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO20091159A NO20091159L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091158A NO20091158L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin
NO20091168A NO20091168L (no)	1999-07-01	2009-03-18	Hoyselektive reopptaksinhibitorer for norepinefrin

Country Status (30)

Country	Link
US (18)	US6465458B1 (de)
EP (3)	EP2087892A3 (de)
JP (3)	JP2003503450A (de)
KR (5)	KR20090087135A (de)
CN (5)	CN1289090C (de)
AR (1)	AR035158A1 (de)
AT (9)	ATE305788T1 (de)
AU (2)	AU771258B2 (de)
BR (1)	BR0012136A (de)
CA (2)	CA2643231A1 (de)
CL (3)	CL2008002866A1 (de)
CO (1)	CO5190662A1 (de)
CZ (1)	CZ299847B6 (de)
DE (9)	DE60020613T2 (de)
DK (4)	DK1196172T3 (de)
EA (6)	EA008381B1 (de)
ES (9)	ES2285645T3 (de)
GE (1)	GEP20094798B (de)
HU (1)	HUP0201623A3 (de)
IL (3)	IL147246A0 (de)
MX (1)	MXPA02000562A (de)
MY (1)	MY137348A (de)
NO (4)	NO20016406L (de)
NZ (2)	NZ515885A (de)
PE (1)	PE20010684A1 (de)
PL (1)	PL196996B1 (de)
PT (5)	PT1196172E (de)
SK (5)	SK286668B6 (de)
TW (9)	TWI298254B (de)
WO (1)	WO2001001973A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE305788T1 (de) *	1999-07-01	2005-10-15	Pharmacia & Upjohn Co Llc	(s,s)-reboxetin zur behandlung von inkontinenz
CA2392879C (en) *	1999-12-01	2005-03-29	Ucb, S.A.	A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
BR0110188A (pt) *	2000-04-21	2003-03-05	Upjohn Co	Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
CA2405565A1 (en)	2000-04-21	2001-11-01	Pharmacia & Upjohn Company	Compounds for treating fibromyalgia and chronic fatigue syndrome
WO2002036125A1 (en) *	2000-10-31	2002-05-10	Head Explorer A/S	The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
EP1395253A2 (de) *	2000-11-15	2004-03-10	Eli Lilly And Company	Behandlung von angstzuständen
WO2002083141A1 (en) *	2001-04-17	2002-10-24	Pharmacia & Upjohn Company	Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) *	2001-05-22	2004-03-11	Bardsley Hazel Judith	New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) *	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
US20040204469A1 (en) *	2001-06-19	2004-10-14	Norbert Muller	Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
US20060167074A1 (en) *	2001-06-19	2006-07-27	Norbert Muller	Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en)	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
US20050014843A1 (en) *	2001-11-30	2005-01-20	Allen Albert John	Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
JP2005517647A (ja) *	2001-12-11	2005-06-16	イーライ・リリー・アンド・カンパニー	ノルエピネフリン再取り込み阻害物質の認知不全処置への使用
US20040102440A1 (en) *	2002-07-01	2004-05-27	Wong Erik Ho Fong	Method of promoting smoking cessation
WO2003068211A1 (en) *	2002-02-12	2003-08-21	Cypress Bioscience, Inc.	Methods of treating attention deficit/hyperactivity disorder (adhd)
MXPA04011529A (es) *	2002-04-24	2005-08-15	Cypress Bioscience Inc	Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
AU2003231788B2 (en) *	2002-05-17	2008-09-11	Duke University	Method for treating obesity
EP1513529B1 (de) *	2002-05-30	2011-12-14	NeuroSearch A/S	Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
PL375211A1 (en) *	2002-06-17	2005-11-28	Pharmacia Italia S.P.A.	Pharmaceutical salts of reboxetine
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
MY136318A (en) *	2002-07-25	2008-09-30	Pharmacia Corp	Sustained-release tablet composition
MXPA05001705A (es) *	2002-08-14	2005-04-19	Pharmacia & Upjohn Co Llc	Uso de reboxetina para el tratamiento de sofocos.
GB0219687D0 (en)	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
EP1546123B1 (de)	2002-08-23	2006-05-31	Eli Lilly And Company	Benzylmorpholinderivate
US7384941B2 (en)	2002-08-23	2008-06-10	Eli Lilly And Company	2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
JP2006504795A (ja) *	2002-10-03	2006-02-09	サイプレスバイオサイエンス，インコーポレイテッド	神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
US20040152710A1 (en) *	2002-10-15	2004-08-05	Deecher Darlene Coleman	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) *	2002-10-15	2008-03-18	Wyeth	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) *	2002-10-15	2004-09-16	Deecher Darlene Coleman	Novel method of treating vasomotor symptoms
US20040204411A1 (en) *	2002-12-17	2004-10-14	Pharmacia Corporation	Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2285407T3 (es) *	2003-01-13	2007-11-16	Dynogen Pharmaceuticals Inc.	Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
KR20050111318A (ko) *	2003-01-13	2005-11-24	다이노젠 파마세우티컬스, 인코포레이티드	기능성 장 질환을 치료하는 방법
CA2519379A1 (en) *	2003-04-04	2004-10-21	Dynogen Pharmaceuticals, Inc.	Method of treating lower urinary tract disorders
KR101167579B1 (ko)	2003-04-29	2012-07-27	오렉시젠 세러퓨틱스 인크.	체중감량용 조성물
US20060105036A1 (en)	2003-05-12	2006-05-18	Stephen Peroutka	Threo-dops controlled release formulation
US8158149B2 (en) *	2004-05-12	2012-04-17	Chelsea Therapeutics, Inc.	Threo-DOPS controlled release formulation
WO2004105690A2 (en) *	2003-05-23	2004-12-09	Cypress Bioscience, Inc.	Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) *	2003-08-22	2003-09-24	Lilly Co Eli	Pyridinylmorpholine derivatives
WO2005020976A2 (en) *	2003-08-27	2005-03-10	Eli Lilly And Company	Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US20070010584A1 (en) *	2003-09-04	2007-01-11	Peroutka Stephen J	Compositions and methods for orthostatic intolerance
ATE449633T1 (de) *	2003-09-12	2009-12-15	Pfizer	Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
US7402698B2 (en)	2003-10-14	2008-07-22	Wyeth	Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en)	2003-10-14	2008-09-02	Wyeth	Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) *	2003-10-14	2005-06-16	Wyeth	Methods of treating vasomotor symptoms
US7531543B2 (en)	2003-10-14	2009-05-12	Wyeth	Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en)	2003-10-14	2009-02-17	Wyeth	Alkanol and cycloalkanol-amine derivatives and methods of their use
US7524846B2 (en)	2003-10-14	2009-04-28	Wyeth	Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7365076B2 (en)	2003-10-14	2008-04-29	Wyeth	Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) *	2003-10-14	2009-06-23	Wyeth	Substituted N-heterocycle derivatives and methods of their use
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
KR20060121178A (ko) *	2003-12-12	2006-11-28	일라이 릴리 앤드 캄파니	일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2005066144A1 (en) *	2003-12-23	2005-07-21	Eli Lilly And Company	Morpholine derivatives as norepinephrine reuptake inhibitors
US7414052B2 (en)	2004-03-30	2008-08-19	Wyeth	Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en)	2004-03-30	2009-04-14	Wyeth	Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) *	2004-04-30	2004-06-09	Pfizer Ltd	Novel compounds
KR100871272B1 (ko) *	2004-04-30	2008-11-28	화이자 인코포레이티드	모폴린 화합물
AP2006003771A0 (en) *	2004-04-30	2006-10-31	Warner Lambert Co	Substituted morpholine compounds for the treatmentof central nervous system disorders
BRPI0511941A (pt) *	2004-06-09	2008-01-22	Pfizer	uso de (s, s)-reboxetina ou reboxetina racêmica
US7244765B2 (en) *	2004-06-25	2007-07-17	Cytokine Pharmasciences, Inc	Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) *	2004-08-10	2009-09-10	Pfizer Inc.	Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
ME01316B (me)	2004-08-13	2013-12-20	Boehringer Ingelheim Int	Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
JP2008514689A (ja) *	2004-10-01	2008-05-08	ニューロキュアリミテッド	Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用
WO2006105117A2 (en) *	2005-03-28	2006-10-05	Dynogen Pharmaceuticals, Inc.	Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
PT2135603E (pt)	2005-11-22	2013-04-03	Orexigen Therapeutics Inc	Composições e métodos para aumentar a sensibilidade à insulina
US20070253994A1 (en) *	2006-04-28	2007-11-01	Medtronic, Inc.	Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
HRP20120479T1 (hr) *	2006-06-28	2012-07-31	Chelsea@Therapeutics@Inc	Farmaceutski sastavi sa droksidopom
WO2008060964A2 (en)	2006-11-09	2008-05-22	Orexigen Therapeutics, Inc.	Unit dosage package and methods for administering weight loss medications
AU2008226541B2 (en)	2007-03-09	2013-05-09	Chelsea Therapeutics, Inc.	Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
WO2008122019A1 (en) *	2007-04-02	2008-10-09	Cypress Biosciences, Inc.	Improving the tolerability of both mirtazapine and reboxetine by using them in combination
JP2010526075A (ja) *	2007-04-30	2010-07-29	アドローコーポレイション	（−）−ｅ−１０−ｏｈ−ｎｔの組成物、ならびにそれらの合成および使用のための方法
ES2431570T3 (es) *	2007-05-07	2013-11-27	Chelsea Therapeutics, Inc.	Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
US8580776B2 (en) *	2007-07-10	2013-11-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) *	2008-02-19	2009-09-17	Adolor Corporation	(-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) *	2008-02-19	2009-09-17	Adolor Corporation	Beloxepin and analogs for the treatment of pain
US8475823B2 (en)	2008-04-18	2013-07-02	Medtronic, Inc.	Baclofen formulation in a polyorthoester carrier
US8956642B2 (en)	2008-04-18	2015-02-17	Medtronic, Inc.	Bupivacaine formulation in a polyorthoester carrier
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
ES2434250T3 (es)	2008-07-24	2013-12-16	Theravance, Inc.	Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) *	2008-09-06	2010-03-18	Bionevia Pharmaceuticals, Inc.	Novel forms of reboxetine
WO2010044016A1 (en) *	2008-10-17	2010-04-22	Pfizer Limited	Novel uses for esreboxetine and racemic reboxetine
EP2419405A1 (de) *	2009-04-15	2012-02-22	Theravance, Inc.	3-(phenoxypyrrolidin-3-ylmethyl)heteroaryl-, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl- und 3-(heteroarylpyrrolidin-3-ylmethoxy)heterarylverbindungen
AU2010273645B2 (en)	2009-07-13	2014-12-04	Theravance Biopharma R&D Ip, Llc	3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) *	2009-07-21	2012-09-25	Theravance, Inc.	3-phenoxymethylpyrrolidine compounds
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
WO2012051103A1 (en)	2010-10-11	2012-04-19	Theravance, Inc.	Serotonin reuptake inhibitors
US8501964B2 (en)	2010-12-03	2013-08-06	Theravance, Inc.	Serotonin reuptake inhibitors
JP5880913B2 (ja)	2011-05-17	2016-03-09	三郎佐古田	パーキンソン病の体幹症状（姿勢反射異常）の治療剤
PL4104824T3 (pl)	2012-06-06	2025-11-12	Nalpropion Pharmaceuticals Llc	Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
WO2016077724A1 (en)	2014-11-13	2016-05-19	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	(2-amino-4(arylamino)phenyl) carbamates
WO2019245975A1 (en)	2018-06-17	2019-12-26	Axsome Therapeutics, Inc.	Compositions for delivery of reboxetine
US11020402B2 (en)	2018-10-15	2021-06-01	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
US20200147093A1 (en)	2018-10-15	2020-05-14	Axsome Therapeutics, Inc.	Use of esreboxetine to treat nervous system disorders such as fibromyalgia
EP3693020A1 (de) *	2019-02-08	2020-08-12	Burmaster International Group GmbH	Kaliumangereicherte topische formulierungen zur schmerzlinderung und schlafhilfe
CR20220247A (es) *	2019-12-03	2022-08-18	Axsome Therapeutics Inc	Uso de reboxetina para tratar los trastornos del sistema nervioso
US12616702B2 (en)	2019-12-03	2026-05-05	Axsome Therapeutics, Inc.	Use of reboxetine to treat narcolepsy
US12565478B1 (en)	2025-01-21	2026-03-03	Axsome Therapeutics, Inc.	(S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3797494A (en)	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en)	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en)	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US4031894A (en)	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) *	1978-01-20	1984-05-31	Erba Farmitalia	Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) *	1980-03-19	1984-08-14	Matsushita Electric Industrial Co., Ltd.	Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en)	1984-08-02	1984-09-05	Erba Farmitalia	3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) *	1984-11-22	1988-05-11	Erba Farmitalia	Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en)	1985-03-26	1986-06-24	Serotonin Industries Of Charleston	Method and compositions for controlling pain, depression and sedation
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
ZA921292B (en)	1991-02-25	1993-08-23	Lilly Co Eli	Treatment of lower urinary tract disorders.
US5281624A (en)	1991-09-27	1994-01-25	Eli Lilly And Company	N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en)	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en)	1993-11-24	1998-11-11	Lilly Co Eli	Pharmaceutical composition for treatment of incontinence
IL111786A0 (en)	1993-12-01	1995-01-24	Max Planck Gesellschaft	Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
ZA958725B (en)	1994-10-20	1997-04-16	Lilly Co Eli	Treatment of disorders with duloxetine
PL187926B1 (pl)	1996-03-25	2004-11-30	Lilly Co Eli	Kompozycja farmaceutyczna do leczenia bólu
CA2250042A1 (en)	1996-03-25	1997-10-02	Eli Lilly And Company	Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5914333A (en) *	1996-07-31	1999-06-22	Novo Nordisk A/S	Treatment of psychotic disorders
US6572880B2 (en)	1996-10-24	2003-06-03	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
WO1999011208A1 (en)	1997-08-28	1999-03-11	Williams C Donald	Method and composition for transdermal administration of pharmacologic agents
US6290986B1 (en)	1996-10-24	2001-09-18	Pharmaceutical Applications Associates, Llc	Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en)	1996-10-24	2002-11-12	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
US20020015713A1 (en) *	1996-10-24	2002-02-07	Murdock Robert W.	Methods and transdermal compositions for pain relief
ES2125696T3 (es)	1996-11-27	1999-03-01	Pfleger R Chem Fab	Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
KR20000057548A (ko)	1996-12-13	2000-09-25	알프레드 엘. 미첼슨	광학적 전송물질 및 결합재
EP1007041A4 (de)	1997-04-11	2001-03-07	Lilly Co Eli	Zusammensetzung zur behandlung von schmerzen
US5942530A (en)	1997-08-28	1999-08-24	Eli Lilly And Company	Method for treating pain
US6622036B1 (en) *	2000-02-09	2003-09-16	Cns Response	Method for classifying and treating physiologic brain imbalances using quantitative EEG
WO1999015177A1 (en) *	1997-09-23	1999-04-01	Eli Lilly And Company	Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk)	1997-09-23	2003-05-15	Елі Ліллі Енд Компані	Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) *	1997-09-23	2003-06-16	Елі Ліллі Енд Компані	Спосіб лікування розладу поведінки
WO1999020279A1 (en)	1997-10-17	1999-04-29	Eli Lilly And Company	Potentiation of pharmaceuticals
EA200001049A1 (ru) *	1998-04-09	2001-04-23	Фармация Энд Апджон Компани	Новые способы лечения нервных расстройств
US6586427B2 (en) *	1998-04-09	2003-07-01	Pharmacia & Upjohn Company	Treatments for nervous disorders
IT1305322B1 (it) *	1998-04-23	2001-05-04	Pharmacia & Upjohn Spa	Uso di reboxetina per il trattamento di disturbi nervosi
BR9909559A (pt) *	1998-05-08	2000-12-19	Upjohn Co	Novas combinações de drogas
CA2335837A1 (en)	1998-06-29	2000-01-06	Pharmaceuticals Applications Associates, Llc	Methods and transdermal compositions for pain relief
US6331571B1 (en) *	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
ATE305788T1 (de) *	1999-07-01	2005-10-15	Pharmacia & Upjohn Co Llc	(s,s)-reboxetin zur behandlung von inkontinenz
GB2355191A (en) *	1999-10-12	2001-04-18	Laxdale Ltd	Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv)	1999-12-23	1999-12-23	Pharmacia & Upjohn Ab	New formulation, use and method
WO2001062236A2 (en) *	2000-02-24	2001-08-30	Pharmacia & Upjohn Company	New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20050096349A1 (en) *	2003-11-03	2005-05-05	University Of Florida	Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

2000
- 2000-06-22 AT AT04013381T patent/ATE305788T1/de not_active IP Right Cessation
- 2000-06-22 BR BR0012136-3A patent/BR0012136A/pt not_active Application Discontinuation
- 2000-06-22 NZ NZ515885A patent/NZ515885A/en unknown
- 2000-06-22 EP EP09161069A patent/EP2087892A3/de not_active Withdrawn
- 2000-06-22 PT PT00941659T patent/PT1196172E/pt unknown
- 2000-06-22 EP EP09161068A patent/EP2090312A1/de not_active Withdrawn
- 2000-06-22 ES ES05111704T patent/ES2285645T3/es not_active Expired - Lifetime
- 2000-06-22 AU AU56337/00A patent/AU771258B2/en not_active Ceased
- 2000-06-22 EA EA200501496A patent/EA008381B1/ru not_active IP Right Cessation
- 2000-06-22 EA EA200700232A patent/EA011094B1/ru not_active IP Right Cessation
- 2000-06-22 DE DE60020613T patent/DE60020613T2/de not_active Expired - Lifetime
- 2000-06-22 ES ES04025513T patent/ES2258251T3/es not_active Expired - Lifetime
- 2000-06-22 EA EA200801805A patent/EA200801805A1/ru unknown
- 2000-06-22 AT AT04013379T patent/ATE292971T1/de not_active IP Right Cessation
- 2000-06-22 HU HU0201623A patent/HUP0201623A3/hu unknown
- 2000-06-22 NZ NZ533243A patent/NZ533243A/en unknown
- 2000-06-22 ES ES04013382T patent/ES2242175T3/es not_active Expired - Lifetime
- 2000-06-22 ES ES04013381T patent/ES2246485T3/es not_active Expired - Lifetime
- 2000-06-22 PT PT04013383T patent/PT1459751E/pt unknown
- 2000-06-22 ES ES04013379T patent/ES2239311T3/es not_active Expired - Lifetime
- 2000-06-22 IL IL14724600A patent/IL147246A0/xx not_active IP Right Cessation
- 2000-06-22 ES ES04013383T patent/ES2247572T3/es not_active Expired - Lifetime
- 2000-06-22 DE DE60019473T patent/DE60019473T2/de not_active Expired - Lifetime
- 2000-06-22 CZ CZ20014625A patent/CZ299847B6/cs not_active IP Right Cessation
- 2000-06-22 GE GEAP200011110A patent/GEP20094798B/en unknown
- 2000-06-22 ES ES04025514T patent/ES2246488T3/es not_active Expired - Lifetime
- 2000-06-22 US US09/599,213 patent/US6465458B1/en not_active Expired - Lifetime
- 2000-06-22 AT AT04013383T patent/ATE304358T1/de not_active IP Right Cessation
- 2000-06-22 AT AT04023888T patent/ATE305306T1/de not_active IP Right Cessation
- 2000-06-22 SK SK50023-2007A patent/SK286668B6/sk not_active IP Right Cessation
- 2000-06-22 AT AT04013382T patent/ATE296634T1/de not_active IP Right Cessation
- 2000-06-22 AT AT05111704T patent/ATE364386T1/de not_active IP Right Cessation
- 2000-06-22 KR KR1020097015714A patent/KR20090087135A/ko not_active Ceased
- 2000-06-22 PT PT05111704T patent/PT1632234E/pt unknown
- 2000-06-22 CA CA002643231A patent/CA2643231A1/en not_active Abandoned
- 2000-06-22 KR KR1020067017835A patent/KR100935277B1/ko not_active Expired - Fee Related
- 2000-06-22 DK DK00941659T patent/DK1196172T3/da active
- 2000-06-22 DE DE60026704T patent/DE60026704T2/de not_active Expired - Lifetime
- 2000-06-22 SK SK1938-2001A patent/SK286104B6/sk not_active IP Right Cessation
- 2000-06-22 EA EA200200111A patent/EA005029B1/ru not_active IP Right Cessation
- 2000-06-22 CN CNB2004101045256A patent/CN1289090C/zh not_active Expired - Fee Related
- 2000-06-22 AT AT04025514T patent/ATE305307T1/de not_active IP Right Cessation
- 2000-06-22 PL PL352252A patent/PL196996B1/pl not_active IP Right Cessation
- 2000-06-22 KR KR1020057009371A patent/KR100717660B1/ko not_active Expired - Fee Related
- 2000-06-22 EA EA200801806A patent/EA200801806A1/ru unknown
- 2000-06-22 ES ES04023888T patent/ES2246487T3/es not_active Expired - Lifetime
- 2000-06-22 DK DK05111704T patent/DK1632234T3/da active
- 2000-06-22 DE DE60023043T patent/DE60023043T2/de not_active Expired - Lifetime
- 2000-06-22 MX MXPA02000562A patent/MXPA02000562A/es active IP Right Grant
- 2000-06-22 SK SK50021-2007A patent/SK286667B6/sk not_active IP Right Cessation
- 2000-06-22 AT AT04025513T patent/ATE319453T1/de not_active IP Right Cessation
- 2000-06-22 CA CA002375908A patent/CA2375908C/en not_active Expired - Fee Related
- 2000-06-22 CN CN2004101045237A patent/CN1660109A/zh active Pending
- 2000-06-22 CN CN2004101045222A patent/CN1660108A/zh active Pending
- 2000-06-22 CN CN2004101045241A patent/CN1660110A/zh active Pending
- 2000-06-22 CN CNB008084858A patent/CN1205935C/zh not_active Expired - Fee Related
- 2000-06-22 DE DE60035232T patent/DE60035232T2/de not_active Expired - Lifetime
- 2000-06-22 SK SK50022-2007A patent/SK286864B6/sk not_active IP Right Cessation
- 2000-06-22 DE DE60022917T patent/DE60022917T2/de not_active Expired - Fee Related
- 2000-06-22 DE DE60026627T patent/DE60026627T2/de not_active Expired - Fee Related
- 2000-06-22 EA EA200400589A patent/EA006652B1/ru not_active IP Right Cessation
- 2000-06-22 SK SK50024-2007A patent/SK286669B6/sk not_active IP Right Cessation
- 2000-06-22 PT PT04013382T patent/PT1459750E/pt unknown
- 2000-06-22 JP JP2001507467A patent/JP2003503450A/ja active Pending
- 2000-06-22 EP EP00941659A patent/EP1196172B1/de not_active Expired - Lifetime
- 2000-06-22 DE DE60022916T patent/DE60022916T2/de not_active Expired - Fee Related
- 2000-06-22 WO PCT/US2000/017256 patent/WO2001001973A2/en not_active Ceased
- 2000-06-22 KR KR1020097015713A patent/KR100948757B1/ko not_active Expired - Fee Related
- 2000-06-22 ES ES00941659T patent/ES2258010T3/es not_active Expired - Lifetime
- 2000-06-22 DK DK04013382T patent/DK1459750T3/da active
- 2000-06-22 PT PT04013379T patent/PT1459748E/pt unknown
- 2000-06-22 AT AT00941659T patent/ATE320257T1/de not_active IP Right Cessation
- 2000-06-22 KR KR1020017016963A patent/KR100704319B1/ko not_active Expired - Fee Related
- 2000-06-22 DE DE60022692T patent/DE60022692T2/de not_active Expired - Lifetime
- 2000-06-22 DK DK04013381T patent/DK1459749T3/da active
- 2000-06-27 MY MYPI20002899A patent/MY137348A/en unknown
- 2000-06-28 PE PE2000000664A patent/PE20010684A1/es not_active Application Discontinuation
- 2000-06-30 AR ARP000103350A patent/AR035158A1/es unknown
- 2000-07-04 CO CO00049691A patent/CO5190662A1/es not_active Application Discontinuation
- 2000-09-05 TW TW094142126A patent/TWI298254B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124457A patent/TW200920378A/zh unknown
- 2000-09-05 TW TW089113086A patent/TWI245631B/zh not_active IP Right Cessation
- 2000-09-05 TW TW094142131A patent/TWI294779B/zh active
- 2000-09-05 TW TW097124426A patent/TW200914027A/zh unknown
- 2000-09-05 TW TW094142128A patent/TWI298255B/zh not_active IP Right Cessation
- 2000-09-05 TW TW094142132A patent/TWI293250B/zh active
- 2000-09-05 TW TW097124378A patent/TW200922594A/zh unknown
- 2000-09-05 TW TW092137686A patent/TW200407146A/zh unknown
2001
- 2001-12-14 US US10/020,261 patent/US6703389B2/en not_active Expired - Fee Related
- 2001-12-28 NO NO20016406A patent/NO20016406L/no unknown
2002
- 2002-01-04 US US10/037,344 patent/US6610690B2/en not_active Expired - Lifetime
- 2002-01-04 US US10/099,334 patent/US6642235B2/en not_active Expired - Fee Related
- 2002-01-23 US US10/055,663 patent/US6987107B2/en not_active Expired - Fee Related
- 2002-09-26 US US10/255,450 patent/US20030040464A1/en not_active Abandoned
2003
- 2003-09-24 US US10/669,611 patent/US20040058925A1/en not_active Abandoned
2004
- 2004-01-16 US US10/758,864 patent/US7317011B2/en not_active Expired - Fee Related
- 2004-05-18 AU AU2004202096A patent/AU2004202096B2/en not_active Ceased
2006
- 2006-02-07 US US11/348,948 patent/US20060142289A1/en not_active Abandoned
- 2006-02-07 US US11/349,331 patent/US7338953B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,022 patent/US7241762B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,373 patent/US7276503B2/en not_active Expired - Fee Related
- 2006-02-22 JP JP2006045459A patent/JP2006143749A/ja active Pending
- 2006-07-28 US US11/460,775 patent/US20060264436A1/en not_active Abandoned
- 2006-08-02 JP JP2006210418A patent/JP2006321815A/ja active Pending
2007
- 2007-10-30 US US11/928,980 patent/US20080103147A1/en not_active Abandoned
- 2007-10-30 US US11/928,917 patent/US7723334B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/928,812 patent/US20080096890A1/en not_active Abandoned
- 2007-10-30 US US11/928,781 patent/US20080103145A1/en not_active Abandoned
- 2007-11-20 IL IL187512A patent/IL187512A0/en unknown
- 2007-11-20 IL IL187513A patent/IL187513A0/en unknown
2008
- 2008-09-26 CL CL2008002866A patent/CL2008002866A1/es unknown
- 2008-09-26 CL CL2008002867A patent/CL2008002867A1/es unknown
- 2008-09-26 CL CL2008002868A patent/CL2008002868A1/es unknown
2009
- 2009-03-18 NO NO20091159A patent/NO20091159L/no unknown
- 2009-03-18 NO NO20091158A patent/NO20091158L/no unknown
- 2009-03-18 NO NO20091168A patent/NO20091168L/no not_active Application Discontinuation
- 2009-04-27 US US12/430,244 patent/US20090247528A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001001973A3 (en)	2002-01-17
TW200914027A (en)	2009-04-01
US7241762B2 (en)	2007-07-10
CA2375908C (en)	2006-05-30
DE60022916D1 (de)	2006-02-09
DK1459749T3 (da)	2006-01-09
EA006652B1 (ru)	2006-02-24
US6465458B1 (en)	2002-10-15
KR100935277B1 (ko)	2010-01-06
US20040147614A1 (en)	2004-07-29
TW200607512A (en)	2006-03-01
ATE364386T1 (de)	2007-07-15
CO5190662A1 (es)	2002-08-29
US20060128705A1 (en)	2006-06-15
DE60019473D1 (de)	2005-05-19
DE60020613T2 (de)	2006-03-16
GEP20094798B (en)	2009-10-26
EP2087892A2 (de)	2009-08-12
WO2001001973A2 (en)	2001-01-11
AU5633700A (en)	2001-01-22
TW200607509A (en)	2006-03-01
ES2239311T3 (es)	2005-09-16
TWI245631B (en)	2005-12-21
NO20091159L (no)	2002-02-19
CZ299847B6 (cs)	2008-12-10
SK286669B6 (sk)	2009-03-05
KR20090087134A (ko)	2009-08-14
ATE320257T1 (de)	2006-04-15
CA2375908A1 (en)	2001-01-11
DE60026627T2 (de)	2007-02-01
EA200801806A1 (ru)	2008-12-30
BR0012136A (pt)	2002-06-11
DE60026704T2 (de)	2006-10-19
HK1076723A1 (en)	2006-01-27
TW200607511A (en)	2006-03-01
PT1459751E (pt)	2005-11-30
EP1196172B1 (de)	2006-03-15
CN1379672A (zh)	2002-11-13
US20090247528A1 (en)	2009-10-01
AR035158A1 (es)	2004-05-05
DE60019473T2 (de)	2006-02-23
NO20091168L (no)	2002-02-19
PT1459748E (pt)	2005-08-31
TW200922594A (en)	2009-06-01
US20060142289A1 (en)	2006-06-29
US20060135521A1 (en)	2006-06-22
TW200407146A (en)	2004-05-16
EA200700232A1 (ru)	2007-06-29
EP1196172A2 (de)	2002-04-17
US7723334B2 (en)	2010-05-25
SK286104B6 (sk)	2008-03-05
KR100717660B1 (ko)	2007-05-15
PL352252A1 (en)	2003-08-11
US20020107249A1 (en)	2002-08-08
NZ515885A (en)	2004-08-27
KR100948757B1 (ko)	2010-03-23
WO2001001973A8 (en)	2001-05-17
ATE305788T1 (de)	2005-10-15
EP2087892A3 (de)	2009-09-30
US20020061910A1 (en)	2002-05-23
CL2008002868A1 (es)	2009-01-09
US7338953B2 (en)	2008-03-04
SK286668B6 (sk)	2009-03-05
AU2004202096B2 (en)	2005-10-20
CN1289090C (zh)	2006-12-13
PE20010684A1 (es)	2001-06-24
EA200501496A1 (ru)	2006-06-30
US20080103146A1 (en)	2008-05-01
DE60035232T2 (de)	2008-02-14
DE60026704D1 (de)	2006-05-11
HUP0201623A3 (en)	2004-12-28
EA011094B1 (ru)	2008-12-30
JP2006143749A (ja)	2006-06-08
EA200200111A1 (ru)	2002-06-27
JP2006321815A (ja)	2006-11-30
TW200920378A (en)	2009-05-16
US20080103147A1 (en)	2008-05-01
SK19382001A3 (sk)	2002-07-02
EA005029B1 (ru)	2004-10-28
CN1205935C (zh)	2005-06-15
US20060135520A1 (en)	2006-06-22
HUP0201623A2 (en)	2002-09-28
TWI293250B (en)	2008-02-11
ATE319453T1 (de)	2006-03-15
KR20060099544A (ko)	2006-09-19
ES2258010T3 (es)	2006-08-16
KR100704319B1 (ko)	2007-04-09
AU2004202096A1 (en)	2004-06-10
DE60020613D1 (de)	2005-07-07
US7276503B2 (en)	2007-10-02
EA200801805A1 (ru)	2008-12-30
TW200607510A (en)	2006-03-01
CA2643231A1 (en)	2001-01-11
DE60022917T2 (de)	2006-06-29
US6610690B2 (en)	2003-08-26
US20020086864A1 (en)	2002-07-04
US20040058925A1 (en)	2004-03-25
ES2246487T3 (es)	2006-02-16
US7317011B2 (en)	2008-01-08
TWI298255B (en)	2008-07-01
EP2090312A1 (de)	2009-08-19
DE60022692D1 (de)	2005-10-20
DK1459750T3 (da)	2005-08-15
SK286667B6 (sk)	2009-03-05
CZ20014625A3 (cs)	2002-08-14
ATE304358T1 (de)	2005-09-15
CN1660111A (zh)	2005-08-31
CN1660110A (zh)	2005-08-31
DE60035232D1 (de)	2007-07-26
DE60022692T2 (de)	2006-06-22
PT1632234E (pt)	2007-07-09
ES2285645T3 (es)	2007-11-16
ATE292971T1 (de)	2005-04-15
US20080103145A1 (en)	2008-05-01
AU771258B2 (en)	2004-03-18
MY137348A (en)	2009-01-30
ATE305307T1 (de)	2005-10-15
US20020128173A1 (en)	2002-09-12
TWI294779B (en)	2008-03-21
DE60023043D1 (de)	2006-02-16
IL147246A0 (en)	2002-08-14
ATE296634T1 (de)	2005-06-15
US20060264436A1 (en)	2006-11-23
PT1196172E (pt)	2006-05-31
CN1660108A (zh)	2005-08-31
NO20091158L (no)	2002-02-19
US6642235B2 (en)	2003-11-04
CL2008002867A1 (es)	2009-01-09
KR20020015363A (ko)	2002-02-27
US20080096890A1 (en)	2008-04-24
ES2246485T3 (es)	2006-02-16
US20030040464A1 (en)	2003-02-27
KR20090087135A (ko)	2009-08-14
EA200400589A1 (ru)	2004-12-30
DK1632234T3 (da)	2007-09-17
KR20050053799A (ko)	2005-06-08
EA008381B1 (ru)	2007-04-27
HK1049630A1 (en)	2003-05-23
CN1660109A (zh)	2005-08-31
TWI298254B (en)	2008-07-01
ES2242175T3 (es)	2005-11-01
DE60022917D1 (de)	2006-02-09
US6703389B2 (en)	2004-03-09
ES2246488T3 (es)	2006-02-16
DE60022916T2 (de)	2006-07-06
ATE305306T1 (de)	2005-10-15
IL187512A0 (en)	2008-06-05
IL187513A0 (en)	2008-06-05
PT1459750E (pt)	2005-08-31
ES2258251T3 (es)	2006-08-16
DE60026627D1 (de)	2006-05-04
DK1196172T3 (da)	2006-06-19
JP2003503450A (ja)	2003-01-28
NO20016406D0 (no)	2001-12-28
ES2247572T3 (es)	2006-03-01
SK286864B6 (sk)	2009-06-05
US6987107B2 (en)	2006-01-17
PL196996B1 (pl)	2008-02-29
NZ533243A (en)	2005-12-23
MXPA02000562A (es)	2002-07-02
DE60023043T2 (de)	2006-06-14
CL2008002866A1 (es)	2009-01-09

Publication	Publication Date	Title
NO20016406D0 (no)	2001-12-28	Höyselektive norepinefrin-reopptaksinhibitorer
NO20021239L (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20021659D0 (no)	2002-04-08	Biaryleterderivater nyttige som monoamin reopptaksinhibitorer
ATE524441T1 (de)	2011-09-15	Vla-4-inhibitoren
NO20034307L (no)	2003-11-27	Cyklopropylindol-derivater som selektive serotonin- gjenopptaksinhibitorer
NO20030867L (no)	2003-02-25	Hydroksamderivater anvendelig som deacetylaseinhibitorer
CY2014022I2 (el)	2015-12-09	Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
DK1140840T3 (da)	2006-07-31	omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
PT1181017E (pt)	2003-06-30	Inibidores de metaloproteases
NO20015065D0 (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
PT1226136E (pt)	2005-04-29	Inibidores da tirosina quinase
DK1460066T3 (da)	2009-11-02	Piperazinforbindelse som tachykinin-inhibitorer
PT1194404E (pt)	2006-08-31	Inibidores de aspartil-protease
NO20030842L (no)	2003-04-28	Fenoksybenzylaminderivater som selektive serotonin- gjenopptaksinhibitorer
PL364821A1 (en)	2004-12-13	Phenylpiperazines as serotonin reuptake inhibitors
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
PT1339695E (pt)	2006-08-31	Inibidores da farnesiltransferase
PT9674T (pt)	2001-06-29	Embalagem para cigarros
NO20025282D0 (no)	2002-11-04	Peptid-deformylase-inhibitorer
PT9699U (pt)	2003-03-31	Dispositivo retrovisor para ciclistas
ES1046497Y (es)	2001-06-01	Escurridor para mochos
ES1045898Y (es)	2001-04-16	Placas para revestimientos.
ES1043040Y (es)	2000-04-01	Envoltorio para flexometros.
IT249628Y1 (it)	2003-05-20	Dispositivo portafilo per orditoi